Literature DB >> 16249383

VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease.

Rita Fragoso1, Teresa Pereira, Yan Wu, Zhenping Zhu, José Cabeçadas, Sérgio Dias.   

Abstract

The presence of persistent circulating leukemia cells, or engrafted into extramedullary tissues, is a bad prognostic factor for patients with acute leukemia. However, little is known about the mechanisms that regulate the exit of leukemia cells from the bone marrow (BM) microenvironment. We reveal that vascular endothelial growth factor receptor 1 (FLT-1) modulates acute leukemia distribution within the BM, along VEGF and PlGF gradients, regulating leukemia survival and exit into the peripheral circulation. FLT-1 activation on acute lymphoblastic leukemia (ALL) cells results in cell migration and proliferation in vitro, whereas in vivo FLT-1-overexpressing cells accumulate in the BM epiphysis of nonobese diabetic-severe combined immunodeficient (NOD-SCID) recipients and are detected in circulation 2 weeks after inoculation. In turn, FLT-1 neutralization affects leukemia localization (now in the BM diaphysis), increases leukemia apoptosis, and impedes the exit of ALL cells, prolonging the survival of inoculated mice. We demonstrate further that FLT-1-induced cell migration involves actin polymerization and lipid raft formation. Taken together, we show that FLT-1 regulates the BM localization of ALL cells, determining their survival and exit into the circulation and ultimately the survival of inoculated recipients. FLT-1 targeting on subsets of acute leukemias may delay the onset of extramedullary disease, which may be advantageous in combinatorial therapeutic settings.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16249383     DOI: 10.1182/blood-2005-06-2530

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.

Authors:  Jia Ruan; Peter Martin; Morton Coleman; Richard R Furman; Ken Cheung; Adam Faye; Rebecca Elstrom; Mark Lachs; Katherine A Hajjar; John P Leonard
Journal:  Cancer       Date:  2010-06-01       Impact factor: 6.860

2.  MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.

Authors:  Przemyslaw Juszczynski; Scott J Rodig; Jing Ouyang; Evan O'Donnell; Kunihiko Takeyama; Wojciech Mlynarski; Katarzyna Mycko; Tomasz Szczepanski; Anna Gaworczyk; Andrei Krivtsov; Joerg Faber; Amit U Sinha; Gabriel A Rabinovich; Scott A Armstrong; Jeffery L Kutok; Margaret A Shipp
Journal:  Clin Cancer Res       Date:  2010-03-23       Impact factor: 12.531

Review 3.  Stem-cell ecology and stem cells in motion.

Authors:  Thalia Papayannopoulou; David T Scadden
Journal:  Blood       Date:  2008-04-15       Impact factor: 22.113

4.  Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy.

Authors:  Jenny Yao; Xiumin Wu; Guanglei Zhuang; Ian M Kasman; Tobias Vogt; Vernon Phan; Masabumi Shibuya; Napoleone Ferrara; Carlos Bais
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-27       Impact factor: 11.205

5.  Hypoxic adaptation of leukemic cells infiltrating the CNS affords a therapeutic strategy targeting VEGFA.

Authors:  Itaru Kato; Yoko Nishinaka; Masahiro Nakamura; Ayse U Akarca; Akira Niwa; Hiroki Ozawa; Kenichi Yoshida; Makiko Mori; Dapeng Wang; Makiko Morita; Hiroo Ueno; Yusuke Shiozawa; Yuichi Shiraishi; Satoru Miyano; Rajeev Gupta; Katsutsugu Umeda; Kenichiro Watanabe; Katsuyoshi Koh; Souichi Adachi; Toshio Heike; Megumu K Saito; Masashi Sanada; Seishi Ogawa; Teresa Marafioti; Akira Watanabe; Tatsutoshi Nakahata; Tariq Enver
Journal:  Blood       Date:  2017-04-19       Impact factor: 22.113

Review 6.  Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge.

Authors:  Praveen Ramakrishnan Geethakumari; Marc S Hoffmann; Naveen Pemmaraju; Shimin Hu; Jeffrey L Jorgensen; Susan O'Brien; Naval Daver
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-02-02

Review 7.  Placental growth factor: What hematologists need to know.

Authors:  Laura F Newell; Shernan G Holtan
Journal:  Blood Rev       Date:  2016-08-27       Impact factor: 8.250

8.  Effects of autocrine vascular endothelial growth factor (VEGF) in non-small cell lung cancer cell line A549.

Authors:  Ying Wang; Lu Huang; Yunmei Yang; Liqian Xu; Ji Yang; Yue Wu
Journal:  Mol Biol Rep       Date:  2013-03-04       Impact factor: 2.316

Review 9.  PlGF: a multitasking cytokine with disease-restricted activity.

Authors:  Mieke Dewerchin; Peter Carmeliet
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

10.  Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells.

Authors:  Nader Rahimi; Todd E Golde; Rosana D Meyer
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.